{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:19:45Z","timestamp":1791523185933,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To compare the diagnostic performance of [<jats:sup>68<\/jats:sup>Ga]DOTATATE PET\/CT, [<jats:sup>18<\/jats:sup>F]FDG PET\/CT, MRI of the spine, and whole-body CT and MRI for the detection of pheochromocytoma\/paraganglioma (PPGL)\u2013related spinal bone metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Between 2014 and 2020, PPGL participants with spinal bone metastases prospectively underwent [<jats:sup>68<\/jats:sup>Ga]DOTATATE PET\/CT, [<jats:sup>18<\/jats:sup>F]FDG PET\/CT, MRI of the cervical-thoracolumbar spine (MRI<jats:sub>spine<\/jats:sub>), contrast-enhanced MRI of the neck and thoraco-abdominopelvic regions (MRI<jats:sub>WB<\/jats:sub>), and contrast-enhanced CT of the neck and thoraco-abdominopelvic regions\u00a0(CT<jats:sub>WB<\/jats:sub>). Per-patient and per-lesion detection rates were calculated. Counting of spinal bone metastases was limited to a maximum of one lesion per vertebrae. A composite of all functional and anatomic imaging served as an imaging comparator. The McNemar test compared detection rates between the scans. Two-sided <jats:italic>p<\/jats:italic> values were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty-three consecutive participants (mean age, 41.7\u2009\u00b1\u200915.7\u00a0years; females, 22) with MRI<jats:sub>spine<\/jats:sub> were included who also underwent [<jats:sup>68<\/jats:sup>Ga]DOTATATE PET\/CT (<jats:italic>n<\/jats:italic>\u2009=\u200943), [<jats:sup>18<\/jats:sup>F]FDG PET\/CT (<jats:italic>n<\/jats:italic>\u2009=\u200943), MRI<jats:sub>WB<\/jats:sub> (<jats:italic>n<\/jats:italic>\u2009=\u200924), and CT<jats:sub>WB<\/jats:sub> (<jats:italic>n<\/jats:italic>\u2009=\u200933). Forty-one of 43 participants were positive for spinal bone metastases, with 382 lesions on the imaging comparator. [<jats:sup>68<\/jats:sup>Ga]DOTATATE PET\/CT demonstrated a per-lesion detection rate of 377\/382 (98.7%) which was superior compared to [<jats:sup>18<\/jats:sup>F]FDG (72.0%, 275\/382, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), MRI<jats:sub>spine<\/jats:sub> (80.6%, 308\/382, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), MRI<jats:sub>WB<\/jats:sub> (55.3%, 136\/246, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and CT<jats:sub>WB<\/jats:sub> (44.8%, 132\/295, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The per-patient detection rate of [<jats:sup>68<\/jats:sup>Ga]DOTATATE PET\/CT was 41\/41 (100%) which was higher compared to [<jats:sup>18<\/jats:sup>F]FDG PET\/CT\u00a0(90.2%, 37\/41, <jats:italic>p<\/jats:italic>\u2009=\u20090.13), MRI<jats:sub>spine<\/jats:sub> (97.6%, 40\/41, <jats:italic>p<\/jats:italic>\u2009=\u20091.00), MRI<jats:sub>WB<\/jats:sub> (95.7%, 22\/23, <jats:italic>p<\/jats:italic>\u2009=\u20091.00), and CT<jats:sub>WB<\/jats:sub> (81.8%, 27\/33, <jats:italic>p<\/jats:italic>\u2009=\u20090.03).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>[<jats:sup>68<\/jats:sup>Ga]DOTATATE PET\/CT should be the modality of choice in PPGL-related spinal bone metastases due to its superior detection rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical relevance statement<\/jats:title>\n                <jats:p>In a prospective study of 43 pheochromocytoma\/paraganglioma participants with spinal bone metastases, [<jats:sup>68<\/jats:sup>Ga]DOTATATE PET\/CT had a superior per-lesion detection rate of 98.7% (377\/382), compared to [<jats:sup>18<\/jats:sup>F]FDG PET\/CT (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), MRI of the spine (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), whole-body CT (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and whole-body MRI (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec><jats:sec>\n                <jats:title>Key Points<\/jats:title>\n                <jats:p><jats:italic>\u2022 Data regarding head-to-head comparison between functional and anatomic imaging modalities to detect spinal bone metastases in pheochromocytoma\/paraganglioma are limited.<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022<\/jats:italic>\u00a0[<jats:sup><jats:italic>68<\/jats:italic><\/jats:sup><jats:italic>Ga<\/jats:italic>]<jats:italic>DOTATATE PET\/CT had a superior per-lesion detection rate of 98.7% in the detection of spinal bone metastases associated with pheochromocytoma\/paraganglioma compared to other imaging modalities:<\/jats:italic> [<jats:sup><jats:italic>18<\/jats:italic><\/jats:sup><jats:italic>]F-FDG PET\/CT, MRI of the spine, whole-body CT, and whole-body MRI.<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022<\/jats:italic>\u00a0[<jats:sup><jats:italic>68<\/jats:italic><\/jats:sup><jats:italic>Ga<\/jats:italic>]<jats:italic>DOTATATE PET\/CT should be the modality of choice in the evaluation of spinal bone metastases associated with pheochromocytoma\/paraganglioma.<\/jats:italic><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00330-024-10652-4","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T11:14:15Z","timestamp":1713266055000},"page":"6488-6498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Diagnostic performance of [68Ga]DOTATATE PET\/CT, [18F]FDG PET\/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection of spinal bone metastases associated with pheochromocytoma and paraganglioma"],"prefix":"10.1007","volume":"34","author":[{"given":"Abhishek","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Millo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninet","family":"Sinaii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailah","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickey J. M.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Prodanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Saboury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Talvacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Derkyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"O\u2019Sullivan Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice P.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naris","family":"Nilubol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Herscovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Cahid","family":"Civelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Carrasquillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-3767","authenticated-orcid":false,"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"10652_CR1","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.eprac.2022.09.003","volume":"28","author":"K Pacak","year":"2022","unstructured":"Pacak K (2022) New biology of pheochromocytoma and paraganglioma. Endocr Pract 28:1253\u20131269","journal-title":"Endocr Pract"},{"key":"10652_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","volume":"11","author":"D Ta\u00efeb","year":"2023","unstructured":"Ta\u00efeb D, Wanna GB, Ahmad M et al (2023) Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol 11:345\u2013361","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10652_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","volume":"20","author":"D Ta\u00efeb","year":"2024","unstructured":"Ta\u00efeb D, N\u00f6lting S, Perrier ND et al (2024) Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement. Nat Rev Endocrinol 20:168\u2013184","journal-title":"Nat Rev Endocrinol"},{"key":"10652_CR4","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jc.2012-4231","volume":"98","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez M, Palmer JL, Hofmann MC et al (2013) Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 98:1492\u20131497","journal-title":"J Clin Endocrinol Metab"},{"key":"10652_CR5","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1210\/jc.2017-00992","volume":"102","author":"O Hamidi","year":"2017","unstructured":"Hamidi O, Young WF Jr, Iniguez-Ariza NM et al (2017) Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 102:3296\u20133305","journal-title":"J Clin Endocrinol Metab"},{"key":"10652_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1507\/endocrj.EJ17-0368","volume":"65","author":"M Yokomoto-Umakoshi","year":"2018","unstructured":"Yokomoto-Umakoshi M, Umakoshi H, Tsuiki M et al (2018) Paraganglioma as a risk factor for bone metastasis. Endocr J 65:253\u2013260","journal-title":"Endocr J"},{"key":"10652_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234927","volume":"15","author":"S Hong","year":"2020","unstructured":"Hong S, Youk T, Lee SJ, Kim KM, Vajdic CM (2020) Bone metastasis and skeletal-related events in patients with solid cancer: a Korean nationwide health insurance database study. PLoS One 15:e0234927","journal-title":"PLoS One"},{"key":"10652_CR8","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1210\/jc.2012-2356","volume":"97","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Chougnet CN, Habra MA et al (2012) Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97:4040\u20134050","journal-title":"J Clin Endocrinol Metab"},{"key":"10652_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EC-14-0119","volume":"4","author":"K Van Loon","year":"2015","unstructured":"Van Loon K, Zhang L, Keiser J et al (2015) Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect 4:9\u201317","journal-title":"Endocr Connect"},{"key":"10652_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10198-015-0716-7","volume":"17","author":"JJ Body","year":"2016","unstructured":"Body JJ, Pereira J, Sleeboom H et al (2016) Health resource utilization associated with skeletal-related events: results from a retrospective European study. Eur J Health Econ 17:711\u2013721","journal-title":"Eur J Health Econ"},{"key":"10652_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00432-010-0946-0","volume":"137","author":"V Pointillart","year":"2011","unstructured":"Pointillart V, Vital JM, Salmi R, Diallo A, Quan GM (2011) Survival prognostic factors and clinical outcomes in patients with spinal metastases. J Cancer Res Clin Oncol 137:849\u2013856","journal-title":"J Cancer Res Clin Oncol"},{"key":"10652_CR12","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E et al (2019) European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 46:2112\u20132137","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10652_CR13","doi-asserted-by":"publisher","first-page":"R627","DOI":"10.1530\/ERC-19-0165","volume":"26","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Jha A, Treglia G, Pacak K (2019) Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer 26:R627\u2013R652","journal-title":"Endocr Relat Cancer"},{"key":"10652_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.625312","volume":"12","author":"M Patel","year":"2021","unstructured":"Patel M, Tena I, Jha A, Taieb D, Pacak K (2021) Somatostatin receptors and analogs in pheochromocytoma and paraganglioma: old players in a new precision medicine world. Front Endocrinol (Lausanne) 12:625312","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10652_CR15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2967\/jnumed.120.259689","volume":"62","author":"JA Carrasquillo","year":"2021","unstructured":"Carrasquillo JA, Chen CC, Jha A et al (2021) Imaging of pheochromocytoma and paraganglioma. J Nucl Med 62:1033\u20131042","journal-title":"J Nucl Med"},{"key":"10652_CR16","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1177\/0284185118764206","volume":"59","author":"Y Kan","year":"2018","unstructured":"Kan Y, Zhang S, Wang W, Liu J, Yang J, Wang Z (2018) (68)Ga-somatostatin receptor analogs and (18)F-FDG PET\/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. Acta Radiol 59:1466\u20131474","journal-title":"Acta Radiol"},{"key":"10652_CR17","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2967\/jnumed.122.264183","volume":"63","author":"A Jha","year":"2022","unstructured":"Jha A, Patel M, Carrasquillo JA et al (2022) Choice is good at times: the emergence of [64Cu]Cu-DOTATATE-based somatostatin receptor imaging in the era of [68Ga]Ga-DOTATATE. J Nucl Med 63:1300\u20131301","journal-title":"J Nucl Med"},{"key":"10652_CR18","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","volume":"27","author":"A Jha","year":"2021","unstructured":"Jha A, Ta\u00efeb D, Carrasquillo JA et al (2021) High-specific-activity- 131 I-MIBG versus 177 Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 27:2989\u20132995","journal-title":"Clin Cancer Res"},{"key":"10652_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2967\/jnumed.120.259697","volume":"62","author":"JA Carrasquillo","year":"2021","unstructured":"Carrasquillo JA, Chen CC, Jha A, Pacak K, Pryma DA, Lin FI (2021) Systemic radiopharmaceutical therapy of pheochromocytoma and paraganglioma. J Nucl Med 62:1192\u20131199","journal-title":"J Nucl Med"},{"key":"10652_CR20","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","volume":"49","author":"MP Yadav","year":"2022","unstructured":"Yadav MP, Ballal S, Sahoo RK, Bal C (2022) Efficacy and safety of 225 Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur J Nucl Med Mol Imaging 49:1595\u20131606","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10652_CR21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","volume":"63","author":"ES Delpassand","year":"2022","unstructured":"Delpassand ES, Tworowska I, Esfandiari R et al (2022) Targeted alpha-emitter therapy with 212 Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-human, dose-escalation clinical trial. J Nucl Med 63:1326\u20131333","journal-title":"J Nucl Med"},{"key":"10652_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s13139-019-00629-3","volume":"54","author":"A Jha","year":"2020","unstructured":"Jha A, Patel M, Baker E et al (2020) Role of 68 Ga-DOTATATE PET\/CT in a case of SDHB-related pterygopalatine fossa paraganglioma successfully controlled with octreotide. Nucl Med Mol Imaging 54:48\u201352","journal-title":"Nucl Med Mol Imaging"},{"key":"10652_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamaoto.2019.3444","volume":"146","author":"A Jha","year":"2020","unstructured":"Jha A, Nilubol N, Pacak K (2020) Some considerations in treating malignant head and neck paragangliomas. JAMA Otolaryngol Head Neck Surg 146:209\u2013210","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10652_CR24","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","volume":"21","author":"I Janssen","year":"2015","unstructured":"Janssen I, Blanchet EM, Adams K et al (2015) Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 21:3888\u20133895","journal-title":"Clin Cancer Res"},{"key":"10652_CR25","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.3390\/cancers14163886","volume":"14","author":"M Patel","year":"2022","unstructured":"Patel M, Jha A, Ling A et al (2022) Performances of functional and anatomic imaging modalities in succinate dehydrogenase A- related metastatic pheochromocytoma and paraganglioma. Cancers (Basel) 14:3886","journal-title":"Cancers (Basel)"},{"key":"10652_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00259-017-3896-9","volume":"45","author":"A Jha","year":"2018","unstructured":"Jha A, Ling A, Millo C et al (2018) Superiority of (68)Ga-DOTATATE over (18)F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging 45:787\u2013797","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10652_CR27","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","volume":"43","author":"I Janssen","year":"2016","unstructured":"Janssen I, Chen CC, Millo CM et al (2016) PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 43:1784\u20131791","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10652_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40644-023-00521-6","volume":"23","author":"S Prado-Wohlwend","year":"2023","unstructured":"Prado-Wohlwend S, Ballesta-Moratalla M, Torres-Espallardo I et al (2023) Same-day comparative protocol PET\/CT-PET\/MRI [68 Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine. Cancer Imaging 23:4","journal-title":"Cancer Imaging"},{"key":"10652_CR29","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1158\/1078-0432.CCR-15-1073","volume":"21","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Hicks RJ (2015) Moving beyond \u201clumpology\u201d: PET\/CT imaging of pheochromocytoma and paraganglioma. Clin Cancer Res 21:3815\u20133817","journal-title":"Clin Cancer Res"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10652-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-10652-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10652-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T17:15:09Z","timestamp":1726247709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-10652-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["10652"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-10652-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Dr. Karel Pacak.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors, Ninet Sinaii is a biostatistician, has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all adult subjects (patients) or parents along with informed assent from pediatric subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"value":"\u2022 prospective\u2022 diagnostic or prognostic study\u2022 performed at one institution","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}